BICYCLE THERAPEUTICS plc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
BCYC$3.69-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · Ended | ||||||
| · · March 31, | ||||||
| · 2024 · 2023 | ||||||
| Cash flows from operating activities: · · · · | ||||||
| Net loss | | $(26,563) | | $(39,064) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Share-based compensation expense | | 9,282 | | 9,042 | ||
| Depreciation and amortization | | 1,658 | | 1,557 | ||
| Non-cash interest | | | 104 | | | 102 |
| Deferred income tax benefit | | (767) | | | (2,106) | |
| Changes in operating assets and liabilities: | | | | | | |
| Accounts receivable | | — | | 2,519 | ||
| Research and development incentives receivable | | (15,268) | | (6,830) | ||
| Prepaid expenses and other assets | | (8,390) | | (1,735) | ||
| Operating lease right‑of‑use assets | | 1,085 | | 1,009 | ||
| Accounts payable | | (5,923) | | (2,001) | ||
| Accrued expenses and other current liabilities | | (5,412) | | (3,130) | ||
| Operating lease liabilities | | (1,179) | | (1,034) | ||
| Deferred revenue | | (19,555) | | (4,900) | ||
| Other long-term liabilities | | 59 | | 160 | ||
| Net cash used in operating activities | | (70,869) | | (46,411) | ||
| Cash flows from investing activities: | | | ||||
| Purchases of property and equipment | | (12) | | (2,099) | ||
| Net cash used in investing activities | | (12) | | (2,099) | ||
| Cash flows from financing activities: | | | ||||
| Proceeds from the issuance of ADSs, net of issuance costs | | | — | | | 2,716 |
| Proceeds from the exercise of share options and sale of ordinary shares | | | 1,871 | | | 2 |
| Net cash provided by financing activities | | 1,871 | | 2,718 | ||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | | (416) | | 453 | ||
| Net decrease in cash, cash equivalents and restricted cash | | (69,426) | | (45,339) | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 526,970 | | 339,154 | ||
| Cash, cash equivalents and restricted cash at end of period | | $457,544 | | $293,815 | ||
| Reconciliation of cash, cash equivalents and restricted cash | | | | | | |
| Cash and cash equivalents | | $456,997 | | $293,815 | ||
| Restricted cash included in other assets | | | 547 | | | — |
| Total cash, cash equivalents and restricted cash | | $457,544 | | $293,815 | ||
| Supplemental disclosure of cash flow information | | | ||||
| Cash paid for interest | | $686 | | $679 | ||
| Cash paid for amounts included in the measurement of operating lease liabilities | | $1,435 | | $1,351 | ||
| Changes in purchases of property and equipment in accounts payable and accrued expenses | | $26 | | $(1,737) | ||
| Advance billings on deferred revenue included in accounts receivable | | $— | | $50,000 | ||
| Non-cash impact to right-of-use assets and operating lease liabilities | | $— | | $5,849 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.